
CVKD
Healthcare · Biotechnology · $5.4M market cap
$1.510.00 (0.0%)Nov 13, 4:00 PM EST
Next report
Time not confirmed
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +35.3% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 16, 2026 · upcoming | Time not confirmed | -0.91 | — | — |
| Aug 13, 2026 | After the close | -1.16 | -1.14 | +1.7% |
| May 7, 2026 | Before the open | -1.57 | -1.04 | +33.8% |
| Nov 10, 2025 | Before the open | -1.55 | -1.31 | +15.5% |
| Aug 11, 2025 | Before the open | -1.77 | -1.87 | -5.6% |
| May 8, 2025 | After the close | -1.64 | -2.09 | -27.4% |
| Mar 13, 2025 | Time not confirmed | -0.15 | -2.55 | -1600.0% |
| Nov 7, 2024 | After the close | -1.80 | -2.18 | -21.1% |
| Aug 7, 2024 | After the close | -1.80 | -2.25 | -25.0% |
| May 9, 2024 | Before the open | -1.35 | -1.50 | -11.1% |
| Mar 11, 2024 | Before the open | -0.08 | -0.05 | +37.5% |
| Nov 11, 2023 | After the close | — | -0.08 | — |
| Aug 30, 2023 | Time not confirmed | — | -1.35 |
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left…
| — |
| Mar 30, 2023 | Time not confirmed | — | -0.85 | — |
| Sep 22, 2022 | Time not confirmed | — | -0.06 | — |